Last reviewed · How we verify

CINRYZE 1000 — Competitive Intelligence Brief

CINRYZE 1000 (CINRYZE 1000) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: C1 esterase inhibitor (plasma-derived). Area: Immunology / Rare Disease.

phase 3 C1 esterase inhibitor (plasma-derived) Plasma kallikrein; C1 esterase inhibitor Immunology / Rare Disease Biologic Live · refreshed every 30 min

Target snapshot

CINRYZE 1000 (CINRYZE 1000) — Shire. CINRYZE is a plasma kallikrein inhibitor that reduces bradykinin production to prevent acute attacks in hereditary angioedema.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CINRYZE 1000 TARGET CINRYZE 1000 Shire phase 3 C1 esterase inhibitor (plasma-derived) Plasma kallikrein; C1 esterase inhibitor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (C1 esterase inhibitor (plasma-derived) class)

  1. Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CINRYZE 1000 — Competitive Intelligence Brief. https://druglandscape.com/ci/cinryze-1000. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: